FrancophonIA/ELRC3.0 huggingface dataset:
English: The marketing authorisation was renewed on 19 July 2001 and on 19 July 2006.
Estonian: Müügiluba pikendati 19. juulil 2001 ja 19.
English: A booster dose is recommended before the end of the second year of life.
Estonian: Revaktsineerimisannus soovitatakse manustada enne teise eluaasta lõppemist.
English: At least 92% developed protective levels of
Estonian: Vähemalt 92% tekkisid kaitsval tasemel antikehad läkaköha vastu.
English: Their breathing should be monitored for up to three
Estonian: Selliste laste hingamist tuleb jälgida vähemalt kolme päeva
English: The recommended vaccination schedule consists of three doses within the first six months of life, with at least four weeks between each dose.
Estonian: Soovitatav vaktsineerimisskeem näeb ette kolme annuse manustamist esimese kuue elukuu jooksul, kusjuures iga üksikannuse manustamise vahele peab jääma vähemalt neli nädalat.
English: Tritanrix HepB has been studied in six studies involving a total of 872 infants aged between seven and 20 weeks, all of whom received the vaccine.
Estonian: Tritanrix HepB-d uuriti kuues uuringus, milles osales kokku 872 imikut vanuses 7-20 nädalat.
English: If you want more information on the basis of the CHMP recommendations, read the Scientific Discussion (also part
Estonian: Kui soovite lisateavet inimravimite komitee soovituste aluse kohta, lugege palun teadusliku arutelu kokkuvõtet (samuti Euroopa avaliku hindamisaruande osa
English: This means that the toxoids and the parts of the hepatitis B virus are fixed onto aluminium compounds, to stimulate a better immune response.
Estonian: See tähendab, et toksoidid ja B-hepatiidi viiruse osad on kinnitunud alumiiniumiühendi külge, mis stimuleerib tugevamat immuunvastust.
English: The European Commission granted a marketing authorisation valid throughout the EU to GlaxoSmithKline Biologicals s.a. for Tritanrix HepB on 19 July 1996.
Estonian: Euroopa Komisjon väljastas Tritanrix HepB müügiloa, mis kehtib kogu Euroopa Liidu territooriumil, ettevõttele GlaxoSmithKline Biologicals s.a. 19 juulil 1996.
English: The main measure of effectiveness was the production of protective antibodies in the infants after the first set of vaccinations.
Estonian: Peamine tulemusnäitaja oli kaitsvate antikehade tekkimine pärast esimest vaktsineerimiskuuri.
English: Further studies looked at the effects of the vaccine in younger infants and at the persistence of antibody levels after vaccination.
Estonian: Järgmistes uuringutes uuriti vaktsiini toimet noorematele imikutele ja antikehade taseme stabiilsust pärast vaktsineerimist.
English: When an infant is given the vaccine, the immune system recognises the parts of the bacteria and viruses contained in the vaccine as ‘foreign' and makes antibodies against them.
Estonian: Kui väikelapsele manustatakse vaktsiini, siis identifitseerib immuunsüsteem bakterite ja viiruste osad kui võõrkehad ja tekitab nende vastu antikehi.
English: The active substances in Tritanrix HepB have been available in the European Union (EU) for a number of years in other vaccines.
Estonian: Tritanrix HepB toimeained on olnud Euroopa Liidus pikka aega kasutusel teiste vaktsiinide koostises.
English: The surface antigens of the hepatitis B virus are produced by a method known as ‘recombinant DNA technology': they are made by a yeast that has received a gene (DNA), which makes it able to produce the proteins.
Estonian: B-hepatiidi viiruse pinnaantigeene toodetakse rekombinant-DNA-tehnika meetodil: neid toodab pärm, millesse on viidud valkude teket võimaldav geen (DNA).
English: It should also not be used in infants who have had an allergic reaction after being given diphtheria, tetanus, pertussis or hepatitis B vaccines.
Estonian: Seda ei tohi süstida ka imikutele, kellel on esinenud allergiline reaktsioon pärast difteeria, teetanuse, läkaköha või B-hepatiidi vaktsiini manustamist.
English: The studies showed that the production of protective levels of antibodies against diphtheria, tetanus and hepatitis B occurred in at least 98% of the infants.
Estonian: Uuringud näitavad, et difteeria, teetanuse ja B-hepatiidi vastu kaitsvate antikehade tekkimine saavutati vähemalt 98% imikutest.
English: The most common side effects with Tritanrix HepB (seen in more than 1 in 10 doses of the vaccine) are drowsiness, feeding problems, fever, redness, swelling, pain, unusual crying and irritability.
Estonian: Tritanrix HepB kõige sagedamad kõrvalnähud (esinenud enam kui ühe annuse korral kümnest) on uimasus, isutus, palavik, punetus, tursed, valu, ebaharilik nutmine ja kergesti ärrituvus.
English: Tritanrix HepB should not be used in infants who may be hypersensitive (allergic) to any of the active substances or any of the other ingredients.
Estonian: Tritanrix HepB-d ei tohi manustada imikutele, kes on ravimi mis tahes toimeainete või koostisosade suhtes ülitundlikud (allergilised).
English: The additional studies showed that starting vaccination at six weeks was adequate, and that a booster dose is needed in the second year of life in order to maintain protection.
Estonian: Täiendavad uuringud on näidanud, et vaktsineerimise alustamine alates 6. nädalast on optimaalne ja kaitsva toime säilitamiseks tuleb väikelaps revaktsineerida teisel eluaastal.
English: EUROPEAN PUBLIC ASSESSMENT REPORT (EPAR) TRITANRIX HEPB EPAR summary for the public
Estonian: EUROOPA AVALIK HINDAMISARUANNE Tritanrix HepB Kokkuvõte üldsusele
English: It contains toxoids (chemically weakened toxins) from diphtheria and tetanus, inactivated (killed) Bordetella pertussis (a bacterium that causes whooping cough) and parts of the hepatitis B virus as active substances.
Estonian: Ravim sisaldab toimeainena difteeria ja teetanuse toksoide (keemiliselt nõrgestatud toksiinid), inaktiveeritud (surmatud) Bordetella pertussis't (läkaköha põhjustav bakter) ja B-hepatiidi viiruse osi.
English: Tritanrix HepB should be postponed in infants with a severe sudden fever, and it should not be given if the child has had encephalopathy (a brain disease) of unknown cause within seven days of a previous vaccination
Estonian: Tritanrix HepB manustamine tuleb edasi lükata, kui imikul tekib järsku kõrge palavik ja vaktsiini ei tohi kasutada, kui lapsel on esinenud seitsme päeva vältel pärast eelmist läkaköha vastast vaktsineerimist teadmata põhjusega entsefalopaatia (ajuhaigus).
English: If a vaccine against hepatitis B has not been given at birth, Tritanrix HepB can be given as early as eight weeks of age.
Estonian: Kui vahetult pärast sünnitust ei ole B-hepatiidi vastast vaktsiini manustatud, võib Tritanrix HepB-d manustada juba kaheksandal elunädalal.
English: Tritanrix HepB contains small amounts of:
Estonian: Tritanrix HepB sisaldab väheses koguses järgmisi
English: Tritanrix HepB is given by deep injection into a muscle, preferably the thigh.
Estonian: Tritanrix HepB-d manustatakse sügava lihasesisese süstena, eelistatult reide.
English: Tritanrix HepB is a vaccine.
Estonian: Tritanrix HepB on vaktsiin.
English: What is the risk associated with Tritanrix HepB?
Estonian: Mis riskid Tritanrix HepB-ga kaasnevad?
English: How has Tritanrix HepB been studied?
Estonian: Kuidas Tritanrix HepB-d uuriti?
English: The Committee for Medicinal Products for Human Use (CHMP) decided that Tritanrix HepB's benefits are greater than its risks for active immunisation against diphtheria, tetanus, pertussis and hepatitis B in infants from six weeks onwards.
Estonian: Inimravimite komitee jõudis otsusele, et Tritanrix HepB kasulikkus väikelaste immuniseerimiseks (alates kuuendast elunädalast) difteeria, teetanuse, läkaköha ja B-hepatiidi vastu on suurem kui vaktsineerimisega kaasnevad võimalikud riskid.
English: Other information about Tritanrix HepB:
Estonian: Muu teave Tritanrix HepB kohta
English: The full EPAR for Tritanrix HepB can be found here.
Estonian: Euroopa avaliku hindamisaruande täisteksti Tritanrix HepB kohta leiate siit.
English: As for all vaccines, if Tritanrix HepB is used in very premature babies, there is a risk of the babies experiencing apnoea (brief pauses in breathing).
Estonian: Nagu kõigi vaktsiinide puhul, võib ka Tritanrix HepB manustamisel sügavalt enneaegsetele lastele tekkida apnoe (lühiaegne hingamispeetus).
English: • killed whole B. pertussis, the bacterium that causes pertussis;
Estonian: • surmatud Bordetella pertussise bakterid;
English: In areas where hepatitis B is common, vaccination against hepatitis B at birth should be continued as normal, with Tritanrix HepB started at six weeks of age.
Estonian: Piirkondades, kus B-hepatiiti esineb sageli, tuleb vahetult pärast sünnitust jätkata Bhepatiidi vastast vaktsineerimist tavalisel viisil.
English: For the full list of all side effects reported with Tritanrix HepB, see the Package Leaflet.
Estonian: Tritanrix HepB kohta teatatud kõrvalnähtude täieliku loetelu leiate pakendi infolehelt.
English: Tritanrix HepB is a vaccine, which is available as a suspension for injection.
Estonian: Tritanrix HepB on vaktsiin, mida turustatakse süstesuspensioonina.
English: The Committee recommended that Tritanrix HepB be
Estonian: Komitee soovitas anda Tritanrix HepB-le müügiloa.
English: The effects of Tritanrix HepB were first tested in experimental modes before being studied in humans.
Estonian: Enne inimuuringuid kontrolliti Tritanrix HepB toimet muude katsetega.
English: Tritanrix HepB is used to vaccinate infants from six weeks of age against diphtheria, tetanus, pertussis The medicine can only be obtained with a prescription.
Estonian: Tritanrix HepB-d kasutatakse imikute vaktsineerimiseks difteeria, teetanuse, läkaköha ja B-hepatiidi vastu alates kuuendast elunädalast.
English: What benefit has Tritanrix HepB shown during the studies?
Estonian: Milles seisneb uuringute põhjal Tritanrix HepB kasulikkus?
English: The vaccine is ‘adsorbed'.
Estonian: ; neile kõigile manustati vaktsiini.
English: The full EPAR and risk management plan summary for Imlygic can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Estonian: Euroopa avaliku hindamisaruande täistekst ja riskijuhtimiskava kokkuvõte Imlygici kohta on ameti veebilehel: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
English: Imlygic talimogene laherparepvec
Estonian: Imlygic talimogeenlaherparepvek
English: A risk management plan has been developed to ensure that Imlygic is used as safely as possible.
Estonian: Töötati välja riskijuhtimiskava, et tagada Imlygici võimalikult ohutu kasutamine.
English: What measures are being taken to ensure the safe and effective use of Imlygic?
Estonian: Mis meetmeid võetakse, et tagada Imlygici ohutu ja efektiivne kasutamine?
English: The second dose is given three weeks after the first dose and treatment is continued every two weeks for at least six months, unless the doctor considers that the patient is not benefiting from the medicine.
Estonian: Teine annus manustatakse kolm nädalat pärast esimest annust ja ravi jätkatakse iga kahe nädala järel vähemalt kuue kuu jooksul, välja arvatud kui arsti arvates ei ole ravim patsiendile kasulik.
English: Regarding safety, Imlygic was relatively well tolerated and most side effects were mild or moderate in severity.
Estonian: Ohutuse osas oli Imlygic suhteliselt hästi talutav ja enamik kõrvalnähtudest olid kerged või mõõdukad.
English: Other information about Imlygic
Estonian: Muu teave Imlygici kohta
English: What is Imlygic and what is it used for?
Estonian: Mis on Imlygic ja milleks seda kasutatakse?
English: The company has put in place a controlled distribution programme to qualified centres to ensure that the cold storage and handling requirements are observed and to control the distribution to the patients.
Estonian: Ettevõte on välja töötanud kontrollitud jaotusprogrammi kvalifitseeritud keskustele, et tagada külmsäilituse ja käsitsemise nõuete järgimine ning kontrollida ravimi levitamist patsientidele.
English: Response to treatment was defined as reduction by at least 50% in the signs of melanoma.
Estonian: Ravivastus määratleti kui melanoominähtude vähenemine vähemalt 50% võrra.
English: Why is Imlygic approved?
Estonian: Miks Imlygic heaks kiideti?
English: The main measure of effectiveness was the proportion of patients who responded to treatment and for whom the response lasted for at least six months before the patients' health declined or they required another therapy.
Estonian: Efektiivsuse põhinäitaja oli nende patsientide protsent, kellel tekkis ravivastus, mis püsis vähemalt kuus kuud enne tervise halvenemist või muu ravi vajamist.
English: Although Imlygic can enter healthy cells, it is not designed to multiply inside them.
Estonian: Kuigi Imlygic võib siseneda tervetesse rakkudesse, ei saa see seal paljuneda.
English: This is a type of medicine that works by delivering genes into the cells of the body.
Estonian: Need on ravimid, mille toime seisneb geenide viimises organismi rakkudesse.
English: The Agency's Committee for Medicinal Products for Human Use (CHMP) noted that Imlygic is a therapy with a novel mechanism of action which can be a valuable addition to existing therapies for advanced inoperable melanoma, an area of unmet medical need.
Estonian: Euroopa Ravimiameti inimravimite komitee märkis, et Imlygic on uudse toimemehhanismiga ravim, mis võib olla väärtuslik täiendus olemasolevatele kaugelearenenud mitteopereeritava melanoomi ravimitele, mis on vastamata meditsiinilise vajadusega valdkond.
English: Most of these side effects were mild or moderate in severity.
Estonian: Enamik neist kõrvalnähtudest olid kerged kuni mõõdukad.
English: When looking at the subset of patients in the study (249 patients) whose disease had not spread to the lung or other internal organs, 25% (41 out of 163) of patients treated with Imlygic had a sustained response to treatment, compared with around 1% (1 out of 86) of patients treated with GM-CSF.
Estonian: Uuringu ühes alarühmas (249 patsienti, kelle haigus ei olnud levinud kopsudesse ega teistesse siseelunditesse), oli püsiva ravivastusega patsiente Imlygici uuringurühmas 25% (41 patsienti 163st) ja GM-CSF-i uuringurühmas ligikaudu 1% (1 patsient 86st).
English: In patients whose immune system is weak (e.g. patients with HIV), Imlygic may cause more widespread disease.
Estonian: Nõrgenenud immuunsüsteemiga patsientidel (nt HIV-ga patsientidel) võib Imlygic põhjustada raskemat haigust.
English: What are the risks associated with Imlygic?
Estonian: Mis riskid Imlygiciga kaasnevad?
English: Thus, CHMP decided that Imlygic's benefits are greater than its risks and recommended that it be approved for use in the EU.
Estonian: Inimravimite komitee järeldas seetõttu, et Imlygici kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas ravimi kasutamise Euroopa Liidus heaks kiita.
English: For the full list of all side effects and restrictions reported with Imlygic, see the package leaflet.
Estonian: Imlygici kohta teatatud kõrvalnähtude ja piirangute täielik loetelu on pakendi infolehel.
English: It is not intended to provide practical advice on how to use Imlygic.
Estonian: Hindamisaruandes ei anta Imlygici kasutamise praktilisi nõuandeid.
English: Patients will also be provided with educational materials and a patient alert card informing on the risks with the medicine and how to avoid accidental exposure to Imlygic.
Estonian: Ka patsientidele antakse teabematerjalid ja patsiendi hoiatuskaart, mis selgitavad ravimi riske ja seda, kuidas vältida juhuslikku kokkupuudet Imlygiciga.
English: As part of this programme, the medicine will only be supplied to doctors who have received appropriate educational materials on the risk of herpes infection, particularly in patients with an impaired immune system, on the risk of transmission of the virus to healthcare professionals or other close contacts of the patient (accidental exposure), and on the necessary precautions to be taken when administering and disposing of the product.
Estonian: Programmi raames tarnitakse ravimit ainult arstidele, kes on saanud asjakohased teabematerjalid ravimi riskide kohta (herpesnakkuse risk kohta nõrgenenud immuunsüsteemiga patsientidel, viiruse tervishoiutöötajatele või teistele patsientidega kokku puutuvatele inimestele leviku risk (juhuslik kokkupuude)) ning vajalike ettevaatusmeetmete kohta ravimi manustamisel ja hävitamisel.
English: It is derived from a weakened herpes simplex virus 1 (the cold sore virus).
Estonian: See on saadud nõrgestatud 1. tüüpi herpes simplex'i viirusest (ohatiseviirusest).
English: This is a summary of the European public assessment report (EPAR) for Imlygic.
Estonian: See on ravimi Imlygic Euroopa avaliku hindamisaruande kokkuvõte.
English: The study, which lasted 24 months, compared Imlygic with GM-CSF injected under the skin.
Estonian: Uuring kestis 24 kuud ja selles võrreldi Imlygicit naha alla süstitava GM-CSF-iga.
English: The company will also carry out three studies to further characterise the benefits and risks of Imlygic, including a study of Imlygic in patients with advanced melanoma that can be surgically removed.
Estonian: Samuti korraldab ettevõte kolm täiendavat uuringut Imlygici kasulikkuse ja riskide kohta, sealhulgas Imlygici kasutamise kohta kirurgiliselt eemaldatava kaugelearenenud melanoomiga patsientidel.
English: Because Imlygic contains a herpes virus, it may reactivate at a later time causing herpes infections such as cold sores.
Estonian: Et Imlygic sisaldab herpesviirust, võib see hiljem reaktiveeruda, põhjustades herpesnakkusi, näiteks ohatist.
English: Imlygic must not be used in patients with a severely impaired immune system because if the virus gets reactivated, the herpes infection could spread to other parts of the body.
Estonian: Imlygicit ei tohi kasutada immuunsüsteemi raske häirega patsientidel, sest viiruse reaktiveerumisel võib herpesviirus levida organismis mujale.
English: The most common serious side effect (affecting around 2 in 100 people) was cellulitis (infection of the upper layers of the skin).
Estonian: Kõige sagedam raske kõrvanäht (esinenud ligikaudu 2 patsiendil 100st) oli tselluliit (naha pinnakihtide põletik).
English: It is given as an injection into melanoma tumours.
Estonian: Seda manustatakse süstina melanoomkasvajasse.
English: This virus has been modified so it can infect and multiply inside melanoma cells.
Estonian: Viirust on muudetud nii, et see saab nakatada melanoomirakke ja nendes paljuneda.
English: Imlygic has been studied in one main study involving 436 patients with inoperable melanoma that had spread to other parts of the body (but not to bone and brain).
Estonian: Imlygicit on uuritud ühes põhiuuringus, milles osales 436 patsienti, kellel oli mitteopereeritav melanoom, mis oli levinud organismis mujale (kuid mitte luudesse ega peaajju).
English: The volume to be injected depends on the size of the tumour and the number of tumours to be injected.
Estonian: Süstitav kogus oleneb kasvaja suurusest ja kasvajate arvust, millesse ravimit süstitakse.
English: Imlygic is available as a solution for injection in two different strengths.
Estonian: Imlygicit turustatakse süstelahusena kahes tugevuses.
English: The most common side effects with Imlygic (which may affect more than 1 in 4 people) are tiredness, chills, pyrexia (fever), nausea (feeling sick), flu-like illness and pain at the injection site.
Estonian: Imlygici kõige sagedamad kõrvalnähud (võivad esineda enam kui 1 patsiendil 4st) on väsimus, külmavärinad, palavik, iiveldus, gripilaadsed sümptomid ja süstekoha valu.
English: For practical information about using Imlygic, patients should read the package leaflet or contact their doctor or pharmacist.
Estonian: Kui vajate Imlygici kasutamise praktilisi nõuandeid, lugege pakendi infolehte või pöörduge oma arsti või apteekri poole.
English: Patients with inoperable melanoma which had spread to other parts of the body (but not to bone, brain or lung) showed a prolonged reduction in their melanoma tumours when treated with Imlygic, although it is still not known whether this will translate into longer survival.
Estonian: Organismis mujale (kuid mitte luudesse, peaajju ega kopsu) levinud mitteopereeritava melanoomiga patsientidel vähenesid melanoomkasvajad Imlygici-ravi korral pikemaks ajaks, kuigi ei ole veel teada, kas see tähendab ka pikemat elunemust.
English: The active substance in Imlygic, talimogene laherparepvec, is a type of gene therapy called ‘oncolytic virus'.
Estonian: Imlygici toimeaine talimogeenlaherparepvek on geeniteraapiaravimite tüüp, mida nimetatakse onkolüütiliseks viiruseks.
English: Imlygic is a cancer medicine used to treat adults with melanoma (a type of skin cancer) that cannot be surgically removed and that has spread to other parts of the body (but not to bone, lung, brain and other internal organs).
Estonian: Imlygic on vähiravim, mida kasutatakse melanoomi (teatud nahavähk) raviks täiskasvanutel, kui melanoomi ei saa kirurgiliselt eemaldada see on levinud organismis mujale (kuid mitte luudesse, kopsu, peaajju ega teistesse siseelunditesse).
English: The first dose is given using the lower strength of Imlygic, but subsequent doses use the higher strength.
Estonian: Esimese annusena manustatakse väiksema tugevusega Imlygicit, järgmiste annustega suurema tugevusega ravimit.
English: Based on this plan, safety information has been included in the summary of product characteristics and the package leaflet for Imlygic, including the appropriate precautions to be followed by healthcare professionals and patients.
Estonian: Selle alusel lisati Imlygici omaduste kokkuvõttesse ja pakendi infolehele ravimi ohutusteave, kus on ka tervishoiuspetsialistide ja patsientide võetavad meetmed.
English: How is Imlygic used?
Estonian: Kuidas Imlygicit kasutatakse?
English: For more information about treatment with Imlygic, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.
Estonian: Kui vajate Imlygiciga toimuva ravi kohta lisateavet, lugege palun pakendi infolehte (mis on samuti Euroopa avaliku hindamisaruande osa) või pöörduge oma arsti või apteekri poole.
English: What benefits of Imlygic have been shown in studies?
Estonian: Milles seisneb uuringute põhjal Imlygici kasulikkus?
English: Treatment with Imlygic should be started and given under the supervision of a doctor with expertise in the treatment of cancer.
Estonian: Ravi Imglygicitiga tohib alustada üksnes vähiravis kogenud arst ning ravi peab toimuma tema järelevalve all.
English: Imlygic uses the melanoma cells' own machinery to multiply, eventually overwhelming melanoma cells and killing them.
Estonian: Imlygic paljuneb melanoomirakkude mehhanismide abil, mille tulemusel hävitab lõpuks melanoomirakud.
English: How does Imlygic work?
Estonian: Kuidas Imlygic toimib?
English: Imlygic is a type of advanced therapy medicine called a ‘gene therapy product'.
Estonian: Imlygic on geeniteraapiaravimite hulka kuuluv uudne ravim.
English: It contains the active substance talimogene laherparepvec.
Estonian: Ravim sisaldab toimeainena talimogeenlaherparepvekki.
English: This protein stimulates the patient's immune system (the body's natural defences) to recognise and destroy melanoma cells.
Estonian: Lisaks tekib nakatunud melanoomirakkudes Imlygici toimel valku GM-CSF, mis stimuleerib patsiendi immuunsüsteemi (organismi looduslikku kaitsemehhanismi) melanoomirakke ära tundma ja hävitama.
English: This information is presented below.
Estonian: Teave on esitatud allpool.
English: 06 May 2019
Estonian: 6. mai 2019
English: Tell your doctor if you are taking or have recently taken any other medicines.
Estonian: Teatage oma arstile, kui te võtate või olete hiljuti võtnud mis tahes muid ravimeid.
English: Patients 75 years and older
Estonian: 75-aastased ja vanemad patsiendid
English: Ελλάδα Teva Ελλάς Α.Ε.
Estonian: Teva Ελλάς Α.Ε.
English: Medical or healthcare professionals
Estonian: Meditsiini- või tervishoiutöötajad
English: • if you have heart problems.
Estonian: • kui teil on probleeme südamega.
English: Patients were treated without steroid pre-treatment or planned G-CSF support.
Estonian: Patsiente raviti ilma eelneva steroidravita või plaanilise G-CSF toetuseta.
English: Randomised comparative study
Estonian: Randomiseeritud võrdlev uuring
English: Gemcitabine (N=430)
Estonian: Gemtsitabiin (N = 430)